Gilead, Galapagos’ filgotinib hits goals in RA trial

12th September 2018 Uncategorised 0

Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.

More: Gilead, Galapagos’ filgotinib hits goals in RA trial
Source: News